Award of NHS South of England Branded Medicines Framework – Tranche A (Cytokine Modulators, Monoclonal Antibodies, Antiretrovirals)

About

NHS England awarded a contract to AbbVie Ltd, Accord Limited, Allergan Limited, Amgen Limited, Biogen Ltd, Bristol-Myers Squibb Pharmaceuticals Limited, Chugai Pharma, Eli Lilly and Company Limited, Ferring Pharmaceuticals Limited, Gilead Sciences and others for the NHS South of England Branded Medicines framework – Tranche A, covering cytokine modulators, other monoclonal antibodies, and antiretrovirals (Doravirine only) for the Midlands & East and North of England.

The framework comprises three lots: CM/PHR/16/5521/01 with a period from 1 September 2019 to 31 August 2021 and an option to extend up to 24 months; CM/PHR/16/5521/02 for annual tranche cytokine modulators and monoclonal antibodies from 1 September 2019 to 31 August 2020 with an option to extend up to 12 months; and CM/PHR/16/5521/03 for proprietary pharmaceuticals interim 2019 in Midlands & East (1 September 2019 to 29 February 2020) and North of England (1 September 2019 to 28 February 2021).

The contract value is £188,004,961.